Hancock Whitney’s PDL BioPharma, Inc. PDLI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-128,394
| Closed | – | – | 805 |
|
|
2025
Q4 | $0 | Hold |
128,394
| – | – | ﹤0.01% | 809 |
|
|
2025
Q3 | $0 | Sell |
128,394
-2
| -0% | – | ﹤0.01% | 810 |
|
|
2025
Q2 | $0 | Hold |
128,396
| – | – | ﹤0.01% | 794 |
|
|
2025
Q1 | $0 | Hold |
128,396
| – | – | ﹤0.01% | 673 |
|
|
2024
Q4 | $0 | Hold |
128,396
| – | – | ﹤0.01% | 677 |
|
|
2024
Q3 | $0 | Hold |
128,396
| – | – | ﹤0.01% | 638 |
|
|
2024
Q2 | $0 | Hold |
128,396
| – | – | ﹤0.01% | 659 |
|
|
2024
Q1 | $0 | Hold |
128,396
| – | – | ﹤0.01% | 693 |
|
|
2023
Q4 | $0 | Hold |
128,396
| – | – | ﹤0.01% | 652 |
|
|
2023
Q3 | $0 | Hold |
128,396
| – | – | ﹤0.01% | 651 |
|
|
2023
Q2 | $0 | Sell |
128,396
-41,405
| -24% | – | ﹤0.01% | 670 |
|
|
2023
Q1 | $0 | Sell |
169,801
-14,968
| -8% | – | ﹤0.01% | 667 |
|
|
2022
Q4 | $0 | Hold |
184,769
| – | – | ﹤0.01% | 658 |
|
|
2022
Q3 | $0 | Hold |
184,769
| – | – | ﹤0.01% | 675 |
|
|
2022
Q2 | $0 | Hold |
184,769
| – | – | ﹤0.01% | 692 |
|
|
2022
Q1 | $0 | Hold |
184,769
| – | – | ﹤0.01% | 746 |
|
|
2021
Q4 | $0 | Hold |
184,769
| – | – | ﹤0.01% | 707 |
|
|
2021
Q3 | $0 | Hold |
184,769
| – | – | ﹤0.01% | 851 |
|
|
2021
Q2 | $0 | Buy |
+184,769
| New | – | ﹤0.01% | 866 |
|
|
2021
Q1 | – | Sell |
-187,757
| Closed | -$464K | – | 846 |
|
|
2020
Q4 | $464K | Buy |
187,757
+41,793
| +29% | +$102K | 0.02% | 543 |
|
|
2020
Q3 | $460K | Buy |
145,964
+2,587
| +2% | +$8.26K | 0.02% | 528 |
|
|
2020
Q2 | $417K | Sell |
143,377
-50,519
| -26% | -$160K | 0.02% | 546 |
|
|
2020
Q1 | $547K | Buy |
193,896
+73,712
| +61% | +$238K | 0.02% | 498 |
|
|
2019
Q4 | $390K | Sell |
120,184
-96,443
| -45% | -$280K | 0.01% | 616 |
|
|
2019
Q3 | $468K | Sell |
216,627
-38,526
| -15% | -$103K | 0.02% | 608 |
|
|
2019
Q2 | $801K | Buy |
255,153
+2,674
| +1% | +$8.67K | 0.03% | 505 |
|
|
2019
Q1 | $939K | Buy |
252,479
+18,895
| +8% | +$63.8K | 0.03% | 477 |
|
|
2018
Q4 | $677K | Sell |
233,584
-30,515
| -12% | -$83.8K | 0.02% | 499 |
|
|
2018
Q3 | $695K | Sell |
264,099
-28,709
| -10% | -$70.5K | 0.02% | 570 |
|
|
2018
Q2 | $685K | Buy |
+292,808
| New | +$818K | 0.03% | 399 |
|
Other funds holding PDLI
Hancock Whitney's PDLI Position: Q1 2026 in Review
Hancock Whitney sold out of PDL BioPharma, Inc. (PDLI) in Q1 2026, closing a stake of 128,394 shares.
Hancock Whitney first reported a position in PDLI in Q2 2018 and held it in 30 quarters. The position peaked at $939K in Q1 2019. 6 funds tracked by Wall St. Rank hold PDLI as of Q1 2026.
- Hancock Whitney reported no remaining PDL BioPharma, Inc. position as of Q1 2026 after selling out during the quarter.
- Hancock Whitney sold 128,394 PDL BioPharma, Inc. shares in Q1 2026.
- Hancock Whitney first reported a position in PDL BioPharma, Inc. in Q2 2018 and held it in 30 quarters.
- Hancock Whitney's PDL BioPharma, Inc. position peaked at $939K in Q1 2019.
- 6 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q1 2026.
Based on Hancock Whitney's 13F filing for Q1 2026, filed 15 May 2026.